BioMarin Pharmaceutical Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BMRN Nasdaq 2836 www.biomarin.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioMarin Pharmaceutical Inc.

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors - Sep 14th, 2026 7:05 am
Growth Without AI: 8 Stock Picks - Sep 14th, 2026 5:58 am
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Sep 12th, 2026 11:02 am
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence - Sep 9th, 2026 7:05 am
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Sep 9th, 2026 2:23 am
3 Reasons to Avoid BMRN and 1 Stock to Buy Instead - Sep 8th, 2026 7:59 am
3 Value Stocks We Think Twice About - Sep 4th, 2026 4:06 pm
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It? - Sep 4th, 2026 10:26 am
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout - Sep 4th, 2026 1:24 am
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing - Sep 4th, 2026 1:08 am
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset - Sep 3rd, 2026 10:28 am
Avenzo Therapeutics Announces Appointment of Barbara Bodem and Elizabeth Mily to Board of Directors as Independent Directors - Sep 3rd, 2026 7:00 am
BioMarin to Participate in Upcoming Investor Conferences - Sep 2nd, 2026 7:00 am
Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute - Sep 2nd, 2026 4:12 am
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects - Sep 1st, 2026 8:56 am
BioMarin Announces Close of the Alesta Therapeutics Acquisition - Sep 1st, 2026 7:05 am
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged - Aug 31st, 2026 11:30 am
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes - Aug 31st, 2026 6:06 am
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) - Aug 31st, 2026 5:00 am
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea - Aug 31st, 2026 12:00 am